Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $42.02.Don't Miss Our ...

Shares of Verona Pharma stock opened at $41.22 on Tuesday. The stock has a market capitalization of $3.32 billion, a price-to-earnings ratio of -21.47 and a beta of 0.46. The company has a debt-to ...

Centiva Capital LP lowered its stake in shares of Verona Pharma plc (NASDAQ:VRNA – Free Report) by 37.4% in the third quarter ...

While not every stock... Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Verona Pharma (VRNA – Research Report). The company’s shares closed yesterday at $40.20. Pick the best ...

4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...

Verona Pharma plc's (NASDAQ:VRNA) Chief Financial Officer, Mark Hahn, recently sold a significant portion of his holdings in the company. The sale comes as the stock trades near its 52-week high ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Verona Pharma recently got approval for ensifentrine in COPD. Ensifentrine has a differentiated MoA and superior safety profile. Despite a diverse market, Verona will find its own place here.

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...